Organon & Co. (OGN)

20,42 +0,19 (+0,94%) Börsenschluss: 04:00PM EDT

Organon & Co.

30 Hudson Street
Floor 33
Jersey City, NJ 07302
United States
551 430 6900
https://www.organon.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 10.000

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Kevin Ali	CEO & Director	3,82M	N/A	1960
Mr. Matthew M. Walsh	Executive VP & CFO	1,81M	N/A	1967
Mr. Kirke Weaver	Executive VP, General Counsel & Corporate Secretary	1,44M	N/A	1974
Ms. Susanne Gabriele Fiedler	Executive VP & Chief Commercial Officer	1,38M	N/A	1968
Mr. Joseph T. Morrissey Jr.	Executive VP and Head of Manufacturing & Supply	1,54M	N/A	1965
Ms. Rachel A. Stahler	Executive VP & Chief Information Officer	N/A	N/A	1976
Ms. Jennifer Halchak	Head of Investor Relations	N/A	N/A	N/A
Ms. Susan O'Neal	Chief Ethics & Compliance Officer	N/A	N/A	N/A
Ms. Rebecca Lowell Edwards	Chief Communications Officer	N/A	N/A	N/A
Mr. Daniel Karp	Chief Business Development Officer	N/A	N/A	1978

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Corporate Governance

Organon & Co.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 1. Die grundlegenden Scores sind Audit: 5, Vorstand: 1, Shareholderrechte: 2, Kompensation: 2.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.